“We had a highly productive second quarter with promising clinical data continuing to mature from our ongoing oncology trials further supporting our belief that CUE-101, as our lead representative CUE-100 program, has the potential to establish a new standard of care for HPV+ HNSCC patients,” said Daniel Passeri, chief executive officer of Cue Biopharma. “These observations, combined with the ongoing advancements of our prioritized autoimmune programs and the recent implementation of a highly focused, strategic business model underscoring our objectives to proactively manage and mitigate capital access risk, support the transformational potential of our Immuno-STAT™ platform to accomplish our mission of developing breakthrough immunotherapies to establish a new standard of care in the treatment of cancer and autoimmune disease.”
Second Quarter 2024 Financial Results
The Company reported collaboration revenue of $2.7 million and $1.4 million for the three months ended June 30, 2024 and 2023, respectively. The increase was due to the timing of revenue earned from the collaboration and option agreement with Ono Pharmaceutical Co., Ltd.
Research and development expenses were $9.5 million and $10.7 million for the three months ended June 30, 2024 and 2023, respectively. The decrease was primarily due to a decrease in research and laboratory costs and compensation expense.
General and administrative expenses were $3.5 million and $4.2 million for the three months ended June 30, 2024 and 2023, respectively. The decrease was primarily due to decreases in professional fees, employee compensation, overhead, and stock-based compensation expense.
The Company reported collaboration revenue of $4.4 million and $1.6 million for the six months ended June 30, 2024 and 2023, respectively. The increase was due to the timing of revenue earned from the collaboration and option agreement with Ono Pharmaceutical Co., Ltd.
Research and development expenses were $19.7 million and $20.0 million for the six months ended June 30, 2024 and 2023, respectively. The decrease was primarily due to a decrease in research and laboratory costs and stock-based compensation expense, partially offset by an increase in clinical expenses.
General and administrative expenses were $7.7 million and $8.4 million for the six months ended June 30, 2024 and 2023, respectively. The decrease was primarily due to decreases in professional fees and employee compensation.
As of June 30, 2024, the Company had $30.0 million in cash and cash equivalents compared with $48.5 million as of June 30, 2023. We expect our current cash, cash equivalents, and marketable securities to fund operations through the second quarter of 2025.
| Cue Biopharma, Inc. |
| Condensed Consolidated Statement of Operations and Comprehensive Loss
(Unaudited) |
| (In thousands, except share and per share amounts) |
| |
| | | | | | | | | |
| | | Three Months Ended
June 30, | | Six Months Ended
June 30,
|
| | | 2024 | | 2023 | | 2024 | | 2023
|
| Collaboration revenue | $ | 2,658 | | $ | 1,382 | | $ | 4,375 | | $ | 1,570 | |
| Operating expenses: | | | | | | | | |
| General and administrative | | 3,511 | | | 4,249 | | | 7,697 | | | 8,425 | |
| Research and development | | 9,530 | | | 10,650 | | | 19,729 | | | 20,041 | |
| Total operating expenses | | 13,041 | | | 14,899 | | | 27,426 | | | 28,466 | |
| Loss from operations | | (10,383) | | | (13,517) | | | (23,051) | | | (26,896) | |
| Other income (expense): | | | | | | | | |
| Interest income | | 427 | | | 564 | | | 989 | | | 1,056 | |
| Interest expense | | (215) | | | (232) | | | (456) | | | (454) | |
| Total other income, net | | 212 | | | 332 | | | 533 | | | 602 | |
| Net loss | $ | (10,171) | | $ | (13,185) | | $ | (22,518) | | $ | (26,294) | |
| Unrealized gain from available-for-sale securities | | — | | | 34 | | | — | | | 91 | |
| Comprehensive loss | $ | (10,171) | | $ | (13,151) | | $ | (22,518) | | $ | (26,203) | |
| Net loss per common share – basic and diluted | $ | (0.20) | | $ | (0.29) | | $ | (0.45) | | $ | (0.59) | |
| Weighted average common shares outstanding – basic and diluted | | 50,174,756 | | | 44,798,760 | | | 49,822,689 | | | 44,725,875 | |
| |
| Cue Biopharma, Inc. |
| Condensed Consolidated Balance Sheets |
| (Unaudited, In thousands) |
| |
| | | June 30, 2024
| | December 31, 2023
|
| Assets | | | | | | |
| Cash and cash equivalents | $ | 30,029 | | $ | 48,514 | |
| Other assets | | 12,300 | | | 13,016 | |
| Total assets | $ | 42,329 | | $ | 61,530 | |
| Liabilities and stockholders’ equity | | | | | | |
| Liabilities | $ | 20,707 | | $ | 24,445 | |
| Stockholders' equity | | 21,622 | | | 37,085 | |
| Total Liabilities and stockholders’ equity | $ | 42,329 | | $ | 61,530 | |
| |
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company’s belief regarding the potential benefits and applications of its drug candidates and programs, including the transformational potential of the company’s Immuno-STAT™ platform to accomplish its mission of developing breakthrough immunotherapies to establish a new standard of care in the treatment of cancer and autoimmune disease; the near-term and intermediate value creation potential of its autoimmune programs; the company’s intention to preserve the value of its oncology programs; the company’s business strategies, plans and prospects, including those related to the prioritization of CUE-401 and CUE-501, and the potential benefits of the company’s program prioritization and realignment on its burn rate; and the cash runway of the company and the sufficiency of the company’s cash and cash equivalents to fund its operations. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “promise” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s ability to shift its focus to its autoimmune assets and achieve the cost savings that it is projecting; the company’s limited operating history, limited cash and a history of losses; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the company’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the company’s operations and clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to obtain adequate financing to fund its business operations in the future and ability to continue as a going concern; the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
